Track topics on Twitter Track topics that are important to you
Roche’s breast cancer blockbuster Herceptin could face further competition in the US when its patent expires in the coming years, as Amgen-Allergan and Teva-Celltrion said the FDA accepted filings for cheaper biosimilar near-copies. With sales o...
Original Article: Roche's Herceptin facing further biosimilar threats in USNEXT ARTICLE
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...